{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:45:50Z","timestamp":1792683950281,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.rpth.2026.106910","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T15:05:25Z","timestamp":1786806325000},"page":"106910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous MG1113 in severe hemophilia A and B: phase 1b study for safety, pharmacokinetics, and pharmacodynamics"],"prefix":"10.1016","volume":"10","author":[{"given":"Chur-Woo","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jo","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Shil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Ram","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon Hui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5397-8762","authenticated-orcid":false,"given":"Sung Ho","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106910_bib2","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1182\/bloodadvances.2025016497","article-title":"Therapeutic innovations in hemophilia: the essential role of a positive reinvestment cycle","volume":"9","author":"Hermans","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106910_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-024-02130-4","article-title":"Marstacimab: first approval","volume":"85","author":"Lamb","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.rpth.2026.106910_bib4","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40265-023-01912-6","article-title":"Concizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.rpth.2026.106910_bib5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/17474086.2025.2522296","article-title":"Safety and efficacy of marstacimab in patients with hemophilia A and B: a systematic review and meta-analysis","volume":"18","author":"Mokresh","year":"2025","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2026.106910_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/10760296251342968","article-title":"Evaluating the safety and efficacy of concizumab in hemophilia A\/B patients: a systematic review","volume":"31","author":"Siddiqui","year":"2025","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106910_bib7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1055\/s-0038-1646989","article-title":"Modifications of extrinsic pathway inhibitor (EPI) and FXa that affect their ability to interact and to inhibit factor vila\/tissue factor: evidence for a two-step model of inhibition","volume":"60","author":"Warn-Cramer","year":"1988","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106910_bib8","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/rth2.12438","article-title":"MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia","volume":"4","author":"Kwak","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106910_bib9","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1182\/blood-2014-10-604587","article-title":"Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor","volume":"125","author":"Puy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106910_bib10","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106910_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103180","article-title":"Marstacimab, an antitissue factor pathway inhibitor, combined with bypassing agents: effects on thrombin generation and in hemostatically normal rats","volume":"9","author":"Peraza","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106910_bib12","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1208\/s12248-017-0086-4","article-title":"Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor-neutralizing antibody (BAY 1093884) in cynomolgus monkeys","volume":"19","author":"Gu","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.rpth.2026.106910_bib13","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/jth.15244","article-title":"Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics","volume":"19","author":"Kwak","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106910_bib14","first-page":"314","article-title":"Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future","volume":"12","author":"Jim\u00e9nez-Yuste","year":"2014","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2026.106910_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106910_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12185-018-2548-6","article-title":"Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia","volume":"111","author":"Chowdary","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2026.106910_bib17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/hae.14595","article-title":"Befovacimab, an anti-tissue factor pathway inhibitor antibody: early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis","volume":"28","author":"Mancuso","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106910_bib18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106910_bib19","series-title":"WFH and NBDF statement on severe adverse event with marstacimab rebalancing agent for hemophilia","author":"Semienchuk","year":"2025"},{"key":"10.1016\/j.rpth.2026.106910_bib21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106910_bib22","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/jth.14272","article-title":"A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A","volume":"16","author":"Eichler","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106910_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jcph.1545","article-title":"Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds","volume":"60","author":"An","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2026.106910_bib24","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106910_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1385\/CT:1:2:141","article-title":"Markers of platelet activation and thrombin generation","volume":"1","author":"Becker","year":"2001","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.rpth.2026.106910_bib26","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood.V59.5.1086.1086","article-title":"Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2\/F1 + 2 fragment and thrombin\u2014antithrombin complex","volume":"59","author":"Teitel","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106910_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1076029607309176","article-title":"Elevated levels of prothrombin fragment 1 + 2 indicate high risk of thrombosis","volume":"14","author":"Ota","year":"2008","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106910_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.thromres.2009.03.002","article-title":"Clinical usefulness of prothrombin fragment 1+2 in patients with suspected pulmonary embolism","volume":"125","author":"Gibson","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106910_bib29","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/ajh.25962","article-title":"Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19)","volume":"95","author":"Al-Samkari","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2026.106910_bib30","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106910_bib31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:26:49Z","timestamp":1792682809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2475037926035685"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106910","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous MG1113 in severe hemophilia A and B: phase 1b study for safety, pharmacokinetics, and pharmacodynamics","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106910"}}